Exelixis (EXEL +3.6%) says it's licensed its PI3K-delta research and development program to...


Exelixis (EXEL +3.6%) says it's licensed its PI3K-delta research and development program to Merck (MRK +0.2%) for $12M plus an additional $239M in combined milestone and royalty payments. The sale will allow the company to focus its energies on developing its lead compound cabozantinib, a potential treatment for cancer.

From other sites
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Hub
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs